Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Novartis Pharmaceuticals515 enrolled

Overview

Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to glimepiride in people with type 2 diabetes not at target blood glucose levels on a sulfonylurea alone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

515

Conditions

Diabetes Mellitus, Type 2

Interventions

vildagliptinDRUG

GlimepirideDRUG

Glimepiride 4 mg qd

LAF237 placeboDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Blood glucose criteria must be met * Previously treated with a sulfonylurea for at least 3 months * Body mass index (BMI) in the range 22-45 Exclusion Criteria: * Type 1 diabetes * Pregnancy or lactation * Evidence of serious cardiovascular complications * Evidence of serious diabetic complications * Laboratory value abnormalities as defined by the protocol * Known sensitivity to glimepiride * Other protocol-defined exclusion criteria may apply

Locations (1)

Novartis Pharmaceuticals

East Hanover, New Jersey, United States

Outcomes

Primary Outcomes

Change from baseline in HbA1c after 24 weeks

Secondary Outcomes

Change from baseline in fasting plasma glucose at 24 weeks

Patients with endpoint HbA1c <7% after 24 weeks

Patients with reduction in HbA1c >/=to 0.7% after 24 weeks

Adverse event profile after 24 weeks of treatment

Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.